Curaleaf Clinic

Today the Sapphire Access Scheme expands to offer £50 appointments to patients. This significant saving marks the success of the UK Medical Cannabis Registry in publishing Real World Evidence in #medicalcannabis Head of Research and Access, Dr Simon Erridge, commented “As a multi-award-winning medical cannabis clinic, we are delighted to further improve access to this treatment option where other therapies haven’t worked. By collecting patient reported outcomes and producing peer reviewed analysis in return, together we inform the wider evidence base of the efficacy and safety of medical cannabis, which is essential for ensuring the correct patients are able to access treatment.” Read more about this news https://lnkd.in/gV3Dq5pu

Curaleaf’s latest report, The Hidden Dangers of Illicit Cannabis, reveals the alarming rise in online illegal cannabis sales, which have grown 50% over the past two years. The unregulated market exposes consumers to potentially serious health risks from mould and lead contamination. Read the full white paper to learn: ➡️ The implications of illicit cannabis for public health and patient safety  ➡️ A range of actions policymakers can take to mitigate the risks  ➡️ Why expanding research into medical cannabis can help to unlock its therapeutic potential Available here thanks to a Curaleaf Clinic and MANDRAKE collaboration: https://shorturl.at/BkT4C #CannabisResearch #MedicalCannabis #CuraleafClinic

Curaleaf Clinic was featured in The Times over the weekend, in an article covering private medical cannabis clinics and access to treatment. Private prescriptions are climbing in the UK and at Curaleaf Clinic alone, we've seen a 42% increase in patients so far this year. Our patient, Sarah, featured in the article and shares her experience with medical cannabis to support her chronic pain from endometriosis. Her story echoes that of the thousands of patients turning to medical cannabis when traditional treatments fail. The article touches on one of the biggest hurdles for patients; the fact that it remains out of reach to those who cannot afford private care or don’t qualify under current NHS guidelines. We believe that these important, public conversations - and the real-life patient outcomes we collect through the UK Medical Cannabis Registry - will help drive meaningful change in terms of patient access. https://lnkd.in/e4N6A_5x (behind paywall)

BBC News shines a spotlight on medical cannabis, discussing the growing demand for access across the UK. NHS access remains limited but Dr Simon Erridge, Research Director at Curaleaf Clinic, who featured in the article, believes that the 2018 legalisation was an important first step towards providing regulated medical care to the estimated 1.8m people self-treating their conditions with illicit cannabis. Read the full article here: https://lnkd.in/eiMGccRn

Curaleaf Clinic will be closed on the 26th of August for the summer bank holiday. Phone lines and live chat will reopen on Tuesday the 27th at 9am.

Traditional fibromyalgia treatments like physical therapy, antidepressants, and pain relievers can sometimes fall short and cause undesirable side effects. As a result, there is growing interest in medical cannabis as an alternative. Read our latest review by Curaleaf Clinic researchers, which explores medical cannabis and fibromyalgia symptoms. https://lnkd.in/d_nJWRVC

At Curaleaf Clinic, we’re proud to lead the way in medical cannabis research. With the help of our patients and the UK Medical Cannabis Registry, we’re able to share research that will help shape the future of medical cannabis globally.    This week, Dr Simon Erridge, Research Director at Curaleaf Clinic, and Dr Mikael Sodergren, Chief Medical Officer at Curaleaf International, are attending the 34th Annual International Cannabinoid Research Society (ICRS) Symposium on Cannabinoids, where they will showcase the latest research from the UK Medical Cannabis Registry.    Read our blog to learn more: https://lnkd.in/eq-2P9WE    #MedicalCannabisUK #ICRS2024 

Curaleaf at Cannabis Europa 2024: What matters to patients? As part of the leading medical cannabis company in Europe, we were thrilled to be the headline sponsors of the Cannabis Europa conference in London. This year's event brought together key players in the industry. In particular, Curaleaf International's spokespeople took the stage to discuss key developments in the European cannabis landscape. Cannabis Europa is one of the leading international conferences where global leaders, innovators, and stakeholders come together annually to explore the latest advancements and regulatory shifts shaping the cannabis industry. Here are the highlights from this industry conference, along with the key takeaways for patients: Raising Awareness in the UK: The UK panel highlighted the need for greater awareness that medical cannabis can be legally prescribed. Curaleaf’s own Jonathan Hodgson emphasised the need for collaboration across the industry to make this happen. Germany's Cannabis Legalisation: Industry experts explored Germany's recent change in cannabis legislation and the removal of cannabis from the narcotics list. They explored how this would reduce barriers to access for patients and its implications for public safety. Commitment to Innovation: Throughout the conference, the importance of research and development was highlighted to ensure that patients are able to access a diverse range of medicines to meet their needs. Changes in Germany and the US are expected to accelerate research which will only help improve patient care here in the UK. Leading the way: At the Business of Cannabis | Europe Awards, Curaleaf International won a total of four awards, including Clinic of the Year. Curaleaf Clinic’s commitment to research, raising awareness, and patient care were all highlighted as reasons why we were recognised with this award. With ongoing advancements and collaborative efforts, we look forward to seeing continued improvements to not only patient access but the care they receive across the industry. #CannabisEuropa #CuraleafInternational #MedicalCannabis #CannabisIndustry #GlobalHealth #InnovationInCannabis

We are pleased to share that our researchers have won the ‘NPPR Article Award 2023’ from the Japanese Society of Neuropsychopharmacology for research conducted using the UK Medical Cannabis Registry.   It is pleasing to see our continued commitment to advancing the evidence on the effects of medical cannabis recognised in this way. Thank you to all our patients who have signed up to the Curaleaf Access Scheme and contribute to the registry - helping us further medical cannabis research together!   Learn more about our research here: https://lnkd.in/eTiKxMYH

We were featured in a recent article by the Mirror alongside Dr. Emeka Okorocha, Dr Simon Erridge, Research Director at Curaleaf Clinic, and our patient Jenn. The article delves into our health desperation campaign, shedding light on the extreme measures individuals are driven to in their battle against chronic pain.   Our campaign is aimed at raising awareness about medical cannabis as an alternative option for those battling chronic pain who haven’t responded to first-line treatments, as shockingly, only 52% of the UK population are aware of its legal availability for medical use.   Dr Emeka Okorocha said: “It’s disheartening to see so many people resorting to extreme measures in an attempt to alleviate their suffering, often with minimal relief. When conventional treatments don’t work, it’s important to explore alternative therapies, but to do so with the input from trained medical professionals. Embracing non-traditional approaches offers hope for those in desperate need, promising relief where conventional methods might have fallen short.”   Read the full article here: https://lnkd.in/eW4aT9_V